^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Vulvar Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/26/2021
    Excerpt:
    …the panel added nivolumab as as second-line, useful in certain circumstances option for HPV-related advanced or recurrent/metastatic vulvar cancer.